Chronic Kidney Disease (CKD)

Categories: Blood diseases, Genetic diseases, Nephrological diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Chronic Kidney Disease

MalaCards integrated aliases for Chronic Kidney Disease:

Name: Chronic Kidney Disease 11 28 5 41 2 14 36 63 16 75 31 33
Chronic Renal Disease 11 14 33
Kidney Failure, Chronic 43 71
Chronic Kidney Failure 11 33
Chronic Renal Failure 75 33
Ckd 11 2
Egfr - [estimated Glomerular Filtration Rate] < 15 Ml/min/1.73m² 33
Ckd - [chronic Kidney Disease] Stage 5 33
Esrd - [end Stage Renal Diseases] 33
Esrf - [end Stage Renal Failure] 33
End Stage Chronic Renal Failure 33
Chronic Renal Failure Syndrome 11
Chronic Kidney Disease Stage 5 71
Ckd - [chronic Kidney Disease] 33
Chronic Hypoxic Kidney Failure 33
Chronic Renal Failure, Stage 5 33
Crf - [chronic Renal Failure] 33
Chronic Renal Insufficiency 33
Chronic Kidney Hypofunction 33
Chronic Kidney Impairment 33
Chronic Renal Suppression 33
Chronic Renal Impairment 33
End Stage Kidney Failure 33
End Stage Kidney Disease 33
End Stage Renal Disease 33
End Stage Renal Failure 33
Renal Failure - Chronic 11
Chronic Kidney Diseases 71
Chronic Kidney Shutdown 33
Chronic Kidney Collapse 33
Chronic Kidney Toxaemia 33
Renal Failure Chronic 53
Crf 11


External Ids:

Disease Ontology 11 DOID:784
ICD9CM 34 585.6
MeSH 43 D007676
NCIt 49 C9438
SNOMED-CT 68 155856009
ICD10 31 N18 N18.5 N18.9
UMLS 71 C0022661 C1561643 C2316810

Summaries for Chronic Kidney Disease

MedlinePlus: 41 You have two kidneys, each about the size of your fist. Their main job is to filter your blood. They remove wastes and extra water, which become urine. They also keep the body's chemicals balanced, help control blood pressure, and make hormones. Chronic kidney disease (CKD) means that your kidneys are damaged and can't filter blood as they should. This damage can cause wastes to build up in your body. It can also cause other problems that can harm your health. Diabetes and high blood pressure are the most common causes of CKD. The kidney damage occurs slowly over many years. Many people don't have any symptoms until their kidney disease is very advanced. Blood and urine tests are the only way to know if you have kidney disease. Treatments cannot cure kidney disease, but they may slow kidney disease. They include medicines to lower blood pressure, control blood sugar, and lower cholesterol. CKD may still get worse over time. Sometimes it can lead to kidney failure. If your kidneys fail, you will need dialysis or a kidney transplantation. You can take steps to keep your kidneys healthier longer: Choose foods with less salt (sodium) Control your blood pressure; your health care provider can tell you what your blood pressure should be Keep your blood sugar in the target range, if you have diabetes Limit the amount of alcohol you drink Choose foods that are healthy for your heart: fruits, vegetables, whole grains, and low-fat dairy foods Lose weight if you are overweight Be physically active Don't smoke NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Chronic Kidney Disease, also known as chronic renal disease, is related to kidney disease and end stage renal disease, and has symptoms including cloudy (hemodialysis) (peritoneal) dialysis effluent An important gene associated with Chronic Kidney Disease is COL4A4 (Collagen Type IV Alpha 4 Chain), and among its related pathways/superpathways are Signal Transduction and Primary focal segmental glomerulosclerosis (FSGS). The drugs Fosinopril and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are homeostasis/metabolism and renal/urinary system

PubMed Health : 63 Chronic kidney disease: Our kidneys are vital organs that clean our blood and affect many different bodily functions. Various medical conditions can cause the kidneys to stop working properly for a short time – for example, if blood isn’t pumped around the body properly or if an enlarged prostate or kidney stones make urine build up in the kidneys. But if the kidneys still aren’t working at full capacity more than three months later or are permanently damaged, then the problem is considered to be chronic kidney disease. The most common causes in adults are diabetes and high blood pressure. Older people are especially prone to developing chronic kidney disease. It often goes unnoticed for a long time because poorly functioning kidneys don’t cause any problems at first. Treatment mostly aims to stop the kidney disease from getting worse, or at least delay the process. It is also important to treat complications such as anemia, acidosis or changes in bone metabolism. If the kidneys fail completely, dialysis or a kidney transplant can prolong the person’s life.

CDC: 2 CKD is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke.

Disease Ontology: 11 A kidney failure that is characterized by the gradual loss of kidney function.

Wikipedia: 75 Chronic kidney disease (CKD) is a type of kidney disease in which a gradual loss of kidney function... more...

Related Diseases for Chronic Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Renal Infectious Disease
Chronic Kidney Disease Ren-Related Kidney Disease

Diseases related to Chronic Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2381)
# Related Disease Score Top Affiliating Genes
1 kidney disease 33.8 WNT9B UMOD PTH PKD2 NPHS2 IL6
2 end stage renal disease 33.5 PKD2 EPO COL4A5 COL4A4 CFH
3 renal osteodystrophy 33.3 PTH FGF23 CASR
4 diabetes mellitus 33.0 UMOD TUG1 PTH IL6 FGF23 EPO
5 hypertension, essential 32.9 UMOD PTH PKD2 NPHS2 IL6 FGF23
6 deficiency anemia 32.9 PTH IL6 EPO CRP CFH ALB
7 hyperparathyroidism 32.8 PTH FGF23 EPO CASR ALB
8 gout 32.8 UMOD PKD2 IL6 CRP ALB
9 nephrotic syndrome, type 24 32.8 NPHS2 AXDND1
10 henoch-schoenlein purpura 32.8 IL6 CRP ALB
11 secondary hyperparathyroidism 32.7 PTH FGF23 EPO CASR ALB
12 calciphylaxis 32.7 PTH FGF23 EPO CASR ALB
13 hyperphosphatemia 32.7 PTH FGF23 CRP CASR ALB
14 rickets 32.7 PTH FGF23 CASR ALB
15 uremia 32.6 PTH IL6 FGF23 EPO CRP CASR
16 nutritional deficiency disease 32.6 IL6 EPO CRP ALB
17 cardiovascular system disease 32.6 PTH IL6 FGF23 CRP ALB
18 cystic kidney disease 32.6 UMOD PTH PKD2 NPHS2 MKS1 FGF23
19 bone disease 32.6 PTH IL6 FGF23 EPO CASR
20 hyperuricemia 32.5 UMOD PTH CRP ALB
21 hypoparathyroidism 32.5 PTH FGF23 CASR
22 glomerulonephritis 32.4 NPHS2 IL6 CRP COL4A5 COL4A4 CFH
23 peripheral vascular disease 32.3 IL6 EPO CRP ALB
24 atherosclerosis susceptibility 32.3 TUG1 IL6 CRP ALB
25 urinary tract infection 32.2 UMOD IL6 CRP ALB
26 acute kidney failure 32.1 UMOD IL6 CFH ALB
27 osteoporosis 32.1 PTH IL6 FGF23 EPO CRP CASR
28 sleep apnea 32.1 IL6 EPO CRP ALB
29 nephrotic syndrome 32.1 NPHS2 IL6 EPO CRP COL4A5 COL4A4
30 polycystic kidney disease 32.0 WNT9B UMOD PTH PKD2 NPHS2 MKS1
31 nephrolithiasis 32.0 UMOD PTH FGF23 CASR
32 iga glomerulonephritis 32.0 NPHS2 IL6 CFH ALB
33 peripheral artery disease 32.0 IL6 CRP ALB
34 focal segmental glomerulosclerosis 32.0 NPHS2 COL4A5 COL4A4 AXDND1 ALB
35 iron deficiency anemia 31.9 IL6 EPO CRP
36 apnea, obstructive sleep 31.9 IL6 CRP ALB
37 interstitial nephritis 31.9 UMOD CRP ALB
38 autosomal dominant polycystic kidney disease 31.9 UMOD PTH PKD2 NPHS2 MKS1 IL6
39 sleep disorder 31.9 IL6 CRP ALB
40 intermediate coronary syndrome 31.9 IL6 CRP ALB
41 urinary tract obstruction 31.9 UMOD IL6 CRP ALB
42 sickle cell anemia 31.8 IL6 EPO CRP ALB
43 cakut 31.8 WNT9B UMOD NPHS2 COL4A5 COL4A4
44 pyelonephritis 31.8 UMOD IL6 CRP ALB
45 urolithiasis 31.7 UMOD IL6 CASR ALB
46 conn's syndrome 31.7 PTH IL6 CRP CASR ALB
47 graves disease 1 31.7 PTH CRP ALB
48 hyperthyroidism 31.7 PTH IL6 CRP ALB
49 proteasome-associated autoinflammatory syndrome 1 31.7 IL6 CRP ALB
50 transient cerebral ischemia 31.7 IL6 CRP ALB

Comorbidity relations with Chronic Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 114)

Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Pancreatitis
Acute Proliferative Glomerulonephritis Acute Vascular Insufficiency of Intestine
Alcoholic Liver Cirrhosis Amyloidosis
Aortic Valve Disease 1 Bacteremia 2
Benign Essential Hypertension Benign Hypertensive Renal Disease
Benign Renovascular Hypertension Bladder Cancer
Bladder Neck Obstruction Bleeding Disorder, Platelet-Type, 11
Bronchitis Bronchopneumonia
Candidiasis Cardiac Arrest
Cardiogenic Shock Cerebral Atherosclerosis
Cerebrovascular Disease Chronic Intestinal Vascular Insufficiency
Chronic Rapidly Progressive Glomerulonephritis Cystitis
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Diabetic Polyneuropathy
Disseminated Intravascular Coagulation Duodenitis
Encephalopathy Esophageal Candidiasis
Esophageal Disease Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Goodpasture Syndrome
Gout Granulomatosis with Polyangiitis
Heart Disease Hemolytic-Uremic Syndrome
Hepatic Encephalopathy Hepatorenal Syndrome
Hydronephrosis Hyperparathyroidism

Graphical network of the top 20 diseases related to Chronic Kidney Disease:

Diseases related to Chronic Kidney Disease

Symptoms & Phenotypes for Chronic Kidney Disease

UMLS symptoms related to Chronic Kidney Disease:

cloudy (hemodialysis) (peritoneal) dialysis effluent

MGI Mouse Phenotypes related to Chronic Kidney Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 ALB CASR CFH COL4A4 COL4A5 CRP
2 renal/urinary system MP:0005367 10.22 ALB CASR CFH COL4A4 COL4A5 FGF23
3 growth/size/body region MP:0005378 10.17 CASR CFH COL4A4 COL4A5 FGF23 IL6
4 cardiovascular system MP:0005385 9.97 ALB CFH COL4A5 CRP EPO FGF23
5 digestive/alimentary MP:0005381 9.91 ALB CASR COL4A4 FGF23 IL6 MKS1
6 immune system MP:0005387 9.8 ALB CASR CFH COL4A4 COL4A5 CRP
7 mortality/aging MP:0010768 9.47 ALB CASR CFH COL4A4 COL4A5 EPO

Drugs & Therapeutics for Chronic Kidney Disease

PubMed Health treatment related to Chronic Kidney Disease: 63

The most suitable treatment for chronic kidney disease will depend on the cause and stage of the disease, as well as on the person’s life circumstances and preferences. If the kidneys are still working at a nearly normal level, treatment should aim to stop or slow down the progression of the disease. This is mainly done using medication to lower blood pressure levels and prevent cardiovascular disease . If you have diabetes , it's important to regulate your blood sugar levels. If complications such as anemia or bone metabolism disorders have already occurred, then more medications are used – such as medicines that contain iron or stimulate the production of blood , as well as medications called “phosphate binders.” If there is too much acid in your body, bicarbonates are used. In addition to the medication, the treatment will include a diet suited to the stage of the disease, drinking the right amounts of liquids and physical exercise . Dialysis or a kidney transplant are considered if the kidneys fail completely. In the vast majority of people with complete kidney failure , at least one of these options is possible. Some people make a conscious decision not to use either, accepting the fact that they could die soon afterwards. Palliative treatment may then be suitable for them – enabling a final phase of life that is as pleasant as possible.

Drugs for Chronic Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 726)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Fosinopril Approved Phase 4 98048-97-6 55891 9601226
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
Capsaicin Approved Phase 4 404-86-4 1548943
Nadroparin Approved, Investigational Phase 4
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
Digoxin Approved Phase 4 20830-75-5 3062 2724385 30322
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2
Sevelamer Approved Phase 4 52757-95-6 3085017
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
Captopril Approved Phase 4 62571-86-2 44093
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
Nifedipine Approved Phase 4 21829-25-4 4485
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
Simvastatin Approved Phase 4 79902-63-9 54454
Amlodipine Approved Phase 4 88150-42-9 2162
Linagliptin Approved Phase 4 668270-12-0 57389748 10096344
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
Ramipril Approved Phase 4 87333-19-5 5362129
Insulin lispro Approved Phase 4 133107-64-9 16132438
Ezetimibe Approved Phase 4 163222-33-1 150311
Rilonacept Approved, Investigational Phase 4 501081-76-1
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
Telavancin Approved Phase 4 372151-71-8 21014972 3081362
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
Amiloride Approved Phase 4 17440-83-4, 2016-88-8, 2609-46-3 16231
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
Ribavirin Approved Phase 4 36791-04-5 37542
Aminophylline Approved Phase 4 317-34-0 9433
Regadenoson Approved, Investigational Phase 4 313348-27-5 22451303 219024
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
Pitavastatin Approved Phase 4 147511-69-1 5282452
Insulin aspart Approved Phase 4 116094-23-6 16132418
Basiliximab Approved, Investigational Phase 4 179045-86-4
Atenolol Approved Phase 4 29122-68-7 2249
Doxazosin Approved Phase 4 74191-85-8 3157
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
Manidipine Approved, Investigational Phase 4 89226-50-6 4008
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
Pamidronic acid Approved Phase 4 40391-99-9 4674

Interventional clinical trials:

(show top 50) (show all 3785)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis:A Multicenter Randomized Controlled Clinical Trial Unknown status NCT04349683 Phase 4 Jinshuibao;Placebo
2 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
3 Effect of Sodium Glucose co Transporter 2 (SGLT2) Inhibition on Optical Coherence Tomography Angiography (OCT-A) Parameters in Diabetic Chronic Kidney Disease (CKD) Unknown status NCT04215445 Phase 4 Empagliflozin 25 MG
4 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
5 Mechanisms of Low Protein Diet Supplemented With α-ketoacids on Autophagy and Improving Muscle Wasting in Chronic Kidney Disease: the Role of Autophagy in Muscle Wasting Unknown status NCT02568020 Phase 4 keto-amino acids
6 The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
7 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
8 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
9 Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
10 COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
11 Gut-kidney Axis: Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids to Restore Physiological Intestinal Mibrobiota in Chronic Kidney Disease Unknown status NCT02302287 Phase 4
12 Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease Unknown status NCT00719316 Phase 4 Aliskiren
13 Research of Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Produced by Immunobiological Technology Institute (Bio-Manguinhos) From Oswaldo Cruz Foundation (Bio-Manguinhos / Fiocruz) Unknown status NCT02648126 Phase 4
14 Lipid-lowering Regimes Improve Oxidative Stress, Tryptophan Degradation in Hypercholesterolemia Chronic Kidney Disease Patients Unknown status NCT03543774 Phase 4 Simvastatin 40mg;Ezetimibe/simvastatin 10/20 mg/day;Ezetimibe/simvastatin 10/40 mg/day
15 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
16 Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03150667 Phase 4 Ticagrelor;Clopidogrel
17 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
18 Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease Unknown status NCT02364648 Phase 4
19 Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) Unknown status NCT03195023 Phase 4 Lisinopril;Amlodipine
20 Comparison of the Effects Between Keto-/Amino Acid Supplemented Low Protein Diet and Non-Supplemented Low Protein Diet in Patients With Stage Ⅴ Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
21 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
22 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril
23 Randomized, Open, Multicenter Study to Evaluate the Renal Function of HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria Unknown status NCT03550859 Phase 4 Telmisartan/Rosuvastatin 40/10mg;Telmisartan 40mg
24 A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD) Unknown status NCT02502981 Phase 4 Spironolactone;Chlortalidone
25 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
26 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
27 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
28 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
29 Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
30 Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4) Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
31 Intradialytic Exercise for Enhanced Dialysis Adequacy and Solute Removal in Chronic Kidney Disease Patients: A Randomised Controlled Trial. Unknown status NCT01481688 Phase 4
32 Phase IV Study for Efficacy and Safety of Evolocumab Added to Ezetimibe (Standard of Care) in High Cardiovascular Risk Haemodialized Statin Intolerant Patients With Hypercholesterolemia Unknown status NCT04659525 Phase 4 Evolocumab;Ezetimibe;Placebo
33 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
34 Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy Unknown status NCT03664414 Phase 4 pentoxifylline
35 Phase IV Study for Efficacy and Safety of Evolocumab Added to Ezetimibe (Standard of Care) in High Cardiovascular Risk Haemodialized Statin Intolerant Patients With Hypercholesterolemia Unknown status NCT04397653 Phase 4 Evolocumab;Placebo;Ezetimibe
36 Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement Unknown status NCT03121053 Phase 4 sodium bicarbonate;hypotone saline
37 Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease Unknown status NCT02452437 Phase 4 Oxycodone
38 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
39 Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy Unknown status NCT01165567 Phase 4 sarpogrelate
40 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease:a Multicentre Open Study Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
41 Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients: Single-centre, Prospective, Observational Study Unknown status NCT03470961 Phase 4 Anti-Tlymphocyte Globulins;Anti-Thymocyte Globulins
42 Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD Unknown status NCT01820832 Phase 4 Calcitriol
43 Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention Unknown status NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
44 Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure Unknown status NCT03682952 Phase 4 Alprostadil Injection;Beraprost sodium tablets
45 Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
46 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
47 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
48 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
49 Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Unknown status NCT01442272 Phase 4 Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
50 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction-a Multicentre, Single Blind, Randomized Controlled, Prospective Trial Unknown status NCT01580046 Phase 4 iodixanol;iopromide

Search NIH Clinical Center for Chronic Kidney Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Aluminum carbonate
basic aluminum carbonate gel
calcium acetate
Calcium Carbonate
Calcium gluceptate
dihydroxyaluminum sodium carbonate
Ethacrynate Sodium
Ethacrynic Acid
Magnesium Hydroxide

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Kidney Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: kidney failure, chronic

Genetic Tests for Chronic Kidney Disease

Genetic tests related to Chronic Kidney Disease:

# Genetic test Affiliating Genes
1 Chronic Kidney Disease 28

Anatomical Context for Chronic Kidney Disease

Organs/tissues related to Chronic Kidney Disease:

MalaCards : Kidney, Bone Marrow, Bone, Heart, Endothelial, Prostate, Liver
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Chronic Kidney Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Kidney Proximal Tubule Proximal Tubule Cells Affected by disease, potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Chronic Kidney Disease

Articles related to Chronic Kidney Disease:

(show top 50) (show all 57272)
# Title Authors PMID Year
Homozygous WNT9B variants in two families with bilateral renal agenesis/hypoplasia/dysplasia. 62 5
34145744 2021
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. 62 41
36411019 2022
Predictive factors for severe long-term chronic kidney disease after acute kidney injury requiring renal replacement therapy in critically ill patients: an ancillary study of the ELVIS randomized controlled trial. 62 41
36447221 2022
Preliminary Exploration of Clinical Efficacy and Pharmacological Mechanism of Modified Danggui-Shaoyao San in the Treatment of Depression in Patients with Chronic Kidney Disease. 62 41
36415742 2022
Mutations in transcription factor CP2-like 1 may cause a novel syndrome with distal renal tubulopathy in humans. 5
33097957 2021
Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle? 53 62
20512104 2010
A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. 53 62
19929273 2010
Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. 53 62
19955654 2010
Insulin resistance as a novel therapeutic target in patients with chronic kidney disease treated with dialysis. 53 62
20150846 2010
A prospective study of brain natriuretic peptide levels in three subgroups: Stroke with hypertension, stroke without hypertension, and hypertension alone. 53 62
20436747 2010
Evaluation of oxidative stress biomarkers in patients with chronic renal failure: a case control study. 53 62
20181004 2010
Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. 53 62
20025585 2009
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. 53 62
19347366 2009
Impact of pancreas transplantation on the quality of life of diabetic renal transplant recipients. 53 62
19857701 2009
Investigation of albumin properties in patients with chronic renal failure. 53 62
19707919 2009
[BNP and echocardiographic parameters in patients with chronic kidney disease and dialyzed patients]. 53 62
19947237 2009
Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. 53 62
19083024 2009
Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. 53 62
19535427 2009
Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. 53 62
19460838 2009
The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. 53 62
19473634 2009
Acute and chronic metabolic acidosis interferes with aquaporin-2 translocation in the rat kidney collecting ducts. 53 62
19300448 2009
Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. 53 62
19096086 2009
Predictive value of C-reactive protein for major postoperative complications following off-pump coronary artery bypass surgery: prospective and observational trial. 53 62
19282606 2009
Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. 53 62
19298916 2009
Ghrelin and other appetite-regulating hormones in paediatric patients with chronic renal failure during dialysis and following kidney transplantation. 53 62
18809976 2009
Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. 53 62
19138652 2009
Leptin and lipid metabolism in chronic kidney failure. 53 62
19148833 2009
Insulin resistance in chronic uremia. 53 62
19121765 2009
New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. 53 62
19494617 2009
Relationships of serum haptoglobin concentration with HbA1c and glycated albumin concentrations in Japanese type 2 diabetic patients. 53 62
19072031 2009
Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. 53 62
19597297 2009
[Insulin resistance and chronic kidney disease]. 53 62
18514051 2008
Effect of a single intravenous immunoglobulin infusion on neutrophil gelatinase-associated lipocalin levels in proteinuric patients with normal renal function. 53 62
18955901 2008
Impact of pancreatic allograft function on 1-year survival rates after simultaneous pancreatic-renal transplant. 53 62
19338493 2008
Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. 53 62
18971153 2008
Recombinant human insulin-like growth factor-1: a new cardiovascular disease treatment option? 53 62
18855638 2008
Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. 53 62
19090870 2008
[The kidneys and hypertension]. 53 62
18770487 2008
Insulin therapy in renal disease. 53 62
18248491 2008
Vitamin D binding protein and the need for vitamin D in hemodialysis patients. 53 62
18721734 2008
[Plasma calcium in haemodialysis patients: total calcium or ionized calcium? Should we systematically provide a value of total corrected calcium on our protocols?]. 53 62
18957349 2008
An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. 53 62
18496509 2008
The effect of chronic renal failure on drug metabolism and transport. 53 62
18680441 2008
Adipocytokines leptin and adiponectin, and measures of malnutrition-inflammation in chronic renal failure: is there a relationship? 53 62
18558297 2008
PHEX, FGF23, DMP1 and beyond. 53 62
18660670 2008
Necrotizing fasciitis. Case report. 53 62
19093634 2008
Vitamin D: an old prohormone with an emergent role in chronic kidney disease. 53 62
18587719 2008
[Peritoneal dialysis and insulin resistance in patients with chronic kidney disease due to nondiabetic nephropathy]. 53 62
18634374 2008
Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs). 53 62
18397721 2008
Urotensin II: a cardiovascular and renal update. 53 62
18277155 2008

Variations for Chronic Kidney Disease

ClinVar genetic disease variations for Chronic Kidney Disease:

5 (show top 50) (show all 53)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 COL4A4 NM_000092.5(COL4A4):c.2906C>G (p.Ser969Ter) SNV Pathogenic
449549 rs35138315 GRCh37: 2:227917083-227917083
GRCh38: 2:227052367-227052367
2 COL4A5 NM_033380.3(COL4A5):c.3614G>T (p.Gly1205Val) SNV Pathogenic
523547 rs1556446493 GRCh37: X:107911558-107911558
GRCh38: X:108668328-108668328
3 PKD2 NM_000297.4(PKD2):c.357_364delinsTAGGACG (p.Pro120fs) INDEL Pathogenic
373955 rs1057518797 GRCh37: 4:88929242-88929249
GRCh38: 4:88008090-88008097
4 MKS1 NM_017777.4(MKS1):c.1115_1117del (p.Ser372del) DEL Pathogenic
217677 rs754279998 GRCh37: 17:56285514-56285516
GRCh38: 17:58208153-58208155
5 COL4A4 NM_000092.5(COL4A4):c.4603_4604del (p.Gln1535fs) DEL Pathogenic
915852 rs1962628992 GRCh37: 2:227872939-227872940
GRCh38: 2:227008223-227008224
6 COL4A4 NM_000092.5(COL4A4):c.2164+2T>G SNV Likely Pathogenic
977307 rs1976595133 GRCh37: 2:227924850-227924850
GRCh38: 2:227060134-227060134
7 TFCP2L1 NM_014553.3(TFCP2L1):c.689del (p.Asp230fs) DEL Likely Pathogenic
1344815 GRCh37: 2:122000014-122000014
GRCh38: 2:121242438-121242438
8 WNT9B, LRRC37A2 NM_003396.3(WNT9B):c.949G>A (p.Gly317Arg) SNV Likely Pathogenic
1344866 GRCh37: 17:44953959-44953959
GRCh38: 17:46876593-46876593
9 WNT9B, LRRC37A2 NM_003396.3(WNT9B):c.11dup (p.Pro5fs) DUP Likely Pathogenic
1344867 GRCh37: 17:44929009-44929010
GRCh38: 17:46851643-46851644
10 NPHS2 NM_014625.4(NPHS2):c.413G>A (p.Arg138Gln) SNV Likely Pathogenic
5360 rs74315342 GRCh37: 1:179530462-179530462
GRCh38: 1:179561327-179561327
11 NPHS2, AXDND1 NM_014625.4(NPHS2):c.855_856del (p.Arg286fs) DEL Likely Pathogenic
188823 rs749740335 GRCh37: 1:179521755-179521756
GRCh38: 1:179552620-179552621
12 SLC13A5 NM_177550.5(SLC13A5):c.231+2T>G SNV Likely Pathogenic
183313 rs730882222 GRCh37: 17:6610345-6610345
GRCh38: 17:6707026-6707026
13 CFH NM_000186.4(CFH):c.2517C>A (p.Cys839Ter) SNV Likely Pathogenic
591005 rs1362306576 GRCh37: 1:196706057-196706057
GRCh38: 1:196736927-196736927
14 FREM1 NM_001379081.2(FREM1):c.1640C>G (p.Ala547Gly) SNV Uncertain Significance
366157 rs201056172 GRCh37: 9:14842412-14842412
GRCh38: 9:14842414-14842414
15 COL4A1 NM_001845.6(COL4A1):c.161C>T (p.Pro54Leu) SNV Uncertain Significance
196327 rs34004222 GRCh37: 13:110866346-110866346
GRCh38: 13:110213999-110213999
16 UMOD NM_003361.4(UMOD):c.1243C>T (p.Arg415Cys) SNV Uncertain Significance
884577 rs758221597 GRCh37: 16:20355434-20355434
GRCh38: 16:20344112-20344112
17 PKD1 NM_001009944.3(PKD1):c.9898G>A (p.Gly3300Arg) SNV Uncertain Significance
427112 rs777024498 GRCh37: 16:2149887-2149887
GRCh38: 16:2099886-2099886
18 APOA1-AS, APOA1 NM_000039.3(APOA1):c.388AAG[1] (p.Lys131del) MICROSAT Uncertain Significance
636899 rs532489785 GRCh37: 11:116706935-116706937
GRCh38: 11:116836219-116836221
19 SOX17 NM_022454.4(SOX17):c.954GCACCA[5] (p.316QH[6]) MICROSAT Uncertain Significance
915867 rs564144826 GRCh37: 8:55372258-55372259
GRCh38: 8:54459698-54459699
20 GANAB NM_198334.3(GANAB):c.925C>T (p.Arg309Cys) SNV Uncertain Significance
716421 rs1063445 GRCh37: 11:62400108-62400108
GRCh38: 11:62632636-62632636
21 CFHR5 NM_030787.4(CFHR5):c.622T>C (p.Cys208Arg) SNV Uncertain Significance
279752 rs41299613 GRCh37: 1:196964861-196964861
GRCh38: 1:196995731-196995731
22 FN1 NM_212482.4(FN1):c.5954C>A (p.Pro1985His) SNV Uncertain Significance
721814 rs148388245 GRCh37: 2:216240375-216240375
GRCh38: 2:215375652-215375652
23 ANLN NM_018685.5(ANLN):c.575C>G (p.Ser192Trp) SNV Uncertain Significance
915855 rs139482132 GRCh37: 7:36445877-36445877
GRCh38: 7:36406268-36406268
24 CFHR5 NM_030787.4(CFHR5):c.486dup (p.Glu163fs) DUP Uncertain Significance
402534 rs565457964 GRCh37: 1:196963258-196963259
GRCh38: 1:196994128-196994129
25 SLC9A3R1 NM_004252.5(SLC9A3R1):c.458G>A (p.Arg153Gln) SNV Uncertain Significance
5271 rs41282065 GRCh37: 17:72758167-72758167
GRCh38: 17:74762028-74762028
26 FN1 NM_212482.4(FN1):c.4486C>T (p.Arg1496Trp) SNV Uncertain Significance
779411 rs139078629 GRCh37: 2:216251538-216251538
GRCh38: 2:215386815-215386815
27 DSTYK NM_015375.3(DSTYK):c.2776G>T (p.Asp926Tyr) SNV Uncertain Significance
915849 rs148542303 GRCh37: 1:205116700-205116700
GRCh38: 1:205147572-205147572
28 ZNF423 NM_001379286.1(ZNF423):c.2275C>T (p.Arg759Cys) SNV Uncertain Significance
645949 rs757246232 GRCh37: 16:49670812-49670812
GRCh38: 16:49636901-49636901
29 EHHADH NM_001966.4(EHHADH):c.2108C>T (p.Ser703Phe) SNV Uncertain Significance
774610 rs55752621 GRCh37: 3:184910078-184910078
GRCh38: 3:185192290-185192290
30 MFF-DT, COL4A3 NM_000091.5(COL4A3):c.1886C>T (p.Thr629Met) SNV Uncertain Significance
452348 rs139361545 GRCh37: 2:228137792-228137792
GRCh38: 2:227273076-227273076
31 FN1 NM_212482.4(FN1):c.1775G>A (p.Arg592His) SNV Uncertain Significance
790514 rs147831535 GRCh37: 2:216284009-216284009
GRCh38: 2:215419286-215419286
32 FN1 NM_212482.4(FN1):c.1070G>A (p.Gly357Glu) SNV Uncertain Significance
791471 rs140926439 GRCh37: 2:216289015-216289015
GRCh38: 2:215424292-215424292
33 ACTN4 NM_004924.6(ACTN4):c.928C>T (p.Arg310Trp) SNV Uncertain Significance
915866 rs756003995 GRCh37: 19:39207741-39207741
GRCh38: 19:38717101-38717101
34 CFHR1 NM_002113.3(CFHR1):c.911A>G (p.Tyr304Cys) SNV Uncertain Significance
915865 rs1376009483 GRCh37: 1:196801047-196801047
GRCh38: 1:196831917-196831917
35 ARHGDIA NM_004309.6(ARHGDIA):c.*243G>A SNV Uncertain Significance
915863 rs189865523 GRCh37: 17:79826509-79826509
GRCh38: 17:81868633-81868633
36 ATIC, FN1 NM_212482.4(FN1):c.7408G>C (p.Ala2470Pro) SNV Uncertain Significance
915862 rs778366340 GRCh37: 2:216226304-216226304
GRCh38: 2:215361581-215361581
37 CFHR1 NM_002113.3(CFHR1):c.727C>G (p.Leu243Val) SNV Uncertain Significance
915861 rs1655514497 GRCh37: 1:196799749-196799749
GRCh38: 1:196830619-196830619
38 APOA1 NM_000039.3(APOA1):c.625G>A (p.Gly209Ser) SNV Uncertain Significance
915860 rs1439470829 GRCh37: 11:116706703-116706703
GRCh38: 11:116835987-116835987
39 EHHADH NM_001966.4(EHHADH):c.594_595del (p.Cys199fs) MICROSAT Uncertain Significance
915857 rs781090244 GRCh37: 3:184922519-184922520
GRCh38: 3:185204731-185204732
40 TBX18 NM_001080508.3(TBX18):c.574G>T (p.Val192Leu) SNV Uncertain Significance
915854 rs201041948 GRCh37: 6:85469998-85469998
GRCh38: 6:84760280-84760280
41 MFF-DT, COL4A3 NM_000091.5(COL4A3):c.4700T>G (p.Ile1567Ser) SNV Uncertain Significance
829912 rs371452712 GRCh37: 2:228173979-228173979
GRCh38: 2:227309263-227309263
42 MT-TF NC_012920.1(MT-CYB):m.643A>G SNV Uncertain Significance
689830 rs1603218472 GRCh37: MT:643-643
GRCh38: MT:643-643
43 CFHR1 NM_002113.3(CFHR1):c.790+1G>A SNV Uncertain Significance
915864 rs140799744 GRCh37: 1:196799813-196799813
GRCh38: 1:196830683-196830683
44 PASK NM_015148.4(PASK):c.3533+1G>A SNV Uncertain Significance
252572 rs140030739 GRCh37: 2:242051654-242051654
GRCh38: 2:241112239-241112239
45 PKD1 NM_001009944.3(PKD1):c.12460C>T (p.Arg4154Cys) SNV Uncertain Significance
803159 rs115538130 GRCh37: 16:2140180-2140180
GRCh38: 16:2090179-2090179
46 FN1 NM_212482.4(FN1):c.3130G>A (p.Val1044Met) SNV Uncertain Significance
915850 rs34043251 GRCh37: 2:216269235-216269235
GRCh38: 2:215404512-215404512
47 WT1, LOC107982234 NM_024426.6(WT1):c.576G>T (p.Gln192His) SNV Uncertain Significance
915856 rs1853438283 GRCh37: 11:32456331-32456331
GRCh38: 11:32434785-32434785
48 CEL NM_001807.6(CEL):c.1966G>C (p.Ala656Pro) SNV Uncertain Significance
128688 rs587780309 GRCh37: 9:135946855-135946855
GRCh38: 9:133071468-133071468
49 ETFB NM_001985.3(ETFB):c.292C>T (p.Arg98Cys) SNV Uncertain Significance
203697 rs147353781 GRCh37: 19:51856469-51856469
GRCh38: 19:51353215-51353215
50 MFF-DT, COL4A3 NM_000091.5(COL4A3):c.346C>A (p.Pro116Thr) SNV Likely Benign
254994 rs115324397 GRCh37: 2:228110691-228110691
GRCh38: 2:227245975-227245975

Expression for Chronic Kidney Disease

Search GEO for disease gene expression data for Chronic Kidney Disease.

Pathways for Chronic Kidney Disease

Pathways related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 13.22 WNT9B PTH MKS1 IL6 FGF23 EPO
2 10.99 NPHS2 COL4A5 COL4A4
3 10.48 NPHS2 COL4A5 COL4A4

GO Terms for Chronic Kidney Disease

Cellular components related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.98 ALB CFH COL4A4 COL4A5 CRP EPO
2 endoplasmic reticulum lumen GO:0005788 9.96 IL6 FGF23 COL4A5 COL4A4 ALB
3 extracellular space GO:0005615 9.66 WNT9B UMOD PTH IL6 FGF23 EPO
4 collagen type IV trimer GO:0005587 9.46 COL4A5 COL4A4

Biological processes related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.23 PTH PKD2 IL6 FGF23 CRP CASR
2 cellular calcium ion homeostasis GO:0006874 9.92 UMOD PTH PKD2 CASR
3 acute-phase response GO:0006953 9.91 IL6 EPO CRP
4 response to fibroblast growth factor GO:0071774 9.78 PTH CASR
5 calcium ion homeostasis GO:0055074 9.67 FGF23 PTH UMOD
6 mesonephric tubule development GO:0072164 9.58 WNT9B PKD2
7 metanephric ascending thin limb development GO:0072218 9.56 UMOD PKD2
8 collecting duct development GO:0072044 9.46 WNT9B UMOD
9 branching morphogenesis of an epithelial tube GO:0048754 9.35 WNT9B MKS1 CASR
10 phosphate ion homeostasis GO:0055062 9.02 UMOD PTH FGF23

Sources for Chronic Kidney Disease

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....